These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 895073)

  • 41. Suppression of delayed hypersensitivity skin reactions to tuberculin by M. leprae antigens in patients with lepromatous and tuberculoid leprosy.
    Sengupta U; Sinha S; Ramu G; Lamb J; Ivanyi J
    Clin Exp Immunol; 1987 Apr; 68(1):58-64. PubMed ID: 3308210
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunological reactions to mycobacterial proteins in the spectrum of leprosy.
    Rada EM; Aranzazu N; Convit J
    Int J Lepr Other Mycobact Dis; 1997 Dec; 65(4):497-500. PubMed ID: 9465162
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunologic responses in patients with lepromatous leprosy.
    Rea TH; Quismorio FP; Harding B; Nies KM; Di Saia PJ; Levan NE; Friou GJ
    Arch Dermatol; 1976 Jun; 112(6):791-800. PubMed ID: 1085131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serological activity of a characteristic phenolic glycolipid from Mycobacterium leprae in sera from patients with leprosy and tuberculosis.
    Brett SJ; Draper P; Payne SN; Rees RJ
    Clin Exp Immunol; 1983 May; 52(2):271-9. PubMed ID: 6407793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of experimental human leprosy in the mouse on leprosy research.
    Rees RJ
    Int J Lepr Other Mycobact Dis; 1971; 39(2):201-15. PubMed ID: 4948076
    [No Abstract]   [Full Text] [Related]  

  • 46. A comparative study on the Mitsuda type response to antigens of chemoautotrophic nocardioform bacteria and to standard lepromin in leprosy patients.
    Chakrabarty AN; Dastidar SG; Chandra AK; Mukherjee M; Chaudhuri SK
    Acta Leprol; 1999; 11(3):105-12. PubMed ID: 10544723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Humoral and cellular immune reactivity to recombinant M. leprae antigens in HLA-typed leprosy patients and healthy controls.
    Klatser PR; Janson AM; Thole JE; Buhrer S; Bos C; Soebono H; de Vries RR
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):178-89. PubMed ID: 9251589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Serodiagnostic monitoring of leprosy].
    Diachina MN
    Probl Tuberk Bolezn Legk; 2003; (11):32-9. PubMed ID: 14689796
    [No Abstract]   [Full Text] [Related]  

  • 49. IgE in leprosy; effect of a Mycobacterium leprae-BCG vaccine.
    Lynch NR; Lopez RI; Ulrich M; Aranzazu N; Convit J
    Int J Lepr Other Mycobact Dis; 1983 Jun; 51(2):169-73. PubMed ID: 6684643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activated suppressor T cells in leprosy.
    Mehra V; Convit J; Rubinstein A; Bloom BR
    J Immunol; 1982 Nov; 129(5):1946-51. PubMed ID: 6214583
    [No Abstract]   [Full Text] [Related]  

  • 51. Immunoprecipitation of mycobacterial antigens with sera from patients with leprosy.
    Kode JA; Chiplunkar SV; Samson PD; Deo MG; Gangal SG
    Acta Leprol; 1994; 9(2):89-94. PubMed ID: 7863757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The suppressive effect of M. leprae on the in vitro proliferative responses of lymphocytes from patients with leprosy.
    Nath I; Singh R
    Clin Exp Immunol; 1980 Sep; 41(3):406-14. PubMed ID: 7002396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rosette-forming cells in patients with treated leprosy.
    Dang DT; Pham MH; Hoang TL; Lai VG; Nguyen HH
    Int J Lepr Other Mycobact Dis; 1983 Jun; 51(2):174-8. PubMed ID: 6684644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The neonatally thymectomized rat as a model of the lepromatous patient.
    Gelber RH
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4 Suppl):879-81. PubMed ID: 3325582
    [No Abstract]   [Full Text] [Related]  

  • 55. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L; Fefer A
    Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract]   [Full Text] [Related]  

  • 56. Evidence of cell-mediated immune contrasuppression in lepromatous leprosy: modulation of a putative T contrasuppressor cell-subset.
    González-Amaro R; Salazar-González JF; Baranda L; Abud-Mendoza C; Moncada B; García R; Alcocer-Varela J
    Clin Exp Immunol; 1988 Mar; 71(3):399-404. PubMed ID: 3133142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae.
    Misra N; Murtaza A; Walker B; Narayan NP; Misra RS; Ramesh V; Singh S; Colston MJ; Nath I
    Immunology; 1995 Sep; 86(1):97-103. PubMed ID: 7590888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Failure of specific antigen presentation in lepromatous leprosy.
    Mathur NK; Jain S; Mathur D; Mangal HN
    Lepr Rev; 1986 Mar; 57(1):78-9. PubMed ID: 3702586
    [No Abstract]   [Full Text] [Related]  

  • 59. Defective cell-mediated immunity in leprosy: failure of T cells from lepromatous leprosy patients to respond to Mycobacterium leprae is associated with defective expression of interleukin 2 receptors and is not reconstituted by interleukin 2.
    Mohagheghpour N; Gelber RH; Larrick JW; Sasaki DT; Brennan PJ; Engleman EG
    J Immunol; 1985 Aug; 135(2):1443-9. PubMed ID: 2989366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The involvement of dendritic cells in the cutaneous lesions associated with tuberculoid and lepromatous leprosy.
    Collings LA; Waters MF; Poulter LW
    Clin Exp Immunol; 1985 Dec; 62(3):458-67. PubMed ID: 3910315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.